NASDAQ:CRSP

Crispr Therapeutics Stock News

etoro logo Buy CRSP
*Your capital is at risk
$48.15
+1.16 (+2.47%)
At Close: Jul 21, 2026
Among the more prominent gene-editing stocks on the market, investors in this space pay particularly close attention to CRISPR Therapeutics (NASDAQ: CRSP ). That's due to the fact that CRISPR is among
Shares of genetic engineering specialist CRISPR Therapeutics (NASDAQ: CRSP ) moved up modestly on Friday as stakeholders await a final regulatory decision regarding a key therapeutic. Earlier, CRISPR

2 Fantastic Growth Stocks to Buy Hand Over Fist

05:00am, Thursday, 26'th Oct 2023
CRISPR Therapeutics may soon launch its first approved product. The economic environment has weighed on Etsy, but recent trends show growth may be reaccelerating.
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

CRISPR Therapeutics Stock: Bull vs. Bear

06:45pm, Saturday, 21'st Oct 2023
The potential for CRISPR Therapeutics' pipeline is tremendous. However, an expected product approval may not offer the stock a huge lift.
Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia,
Superstar investor Wood looks for innovators whose products could be game changers down the road. She goes for companies that are undervalued today considering their long-term potential.
There are a couple of stocks in the healthcare sector that could climb more than 100%, according to consensus estimates from Wall Street analysts. Analysts expecting CRISPR Therapeutics to launch its
Gene-editing stocks have gotten pummeled by the market's growing aversion to risk. Nonetheless, the field has made substantial progress of late.
Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.

BEAM Focuses on Developing Gene Drug for Growth

11:16am, Tuesday, 10'th Oct 2023
While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
Cathie Wood is betting on CRISPR Therapeutics' ability to cure certain diseases through its gene editing techniques. The company is about to reach an important moment -- one that could lead to blockbu
Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA v
In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three c
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE